Alkon would disagree [RE: Amyloid trials]. "These trials are not working, and moving it up earlier and earlier is not going to change it," Alkon said. "Look at Biogen's trial. What people don't realize is that Biogen moved their trial so far up that there wasn't one Alzheimer's patient in the trial. They only looked at people who were mild cognitively impaired or confused. Only half of which go on to get Alzheimer's."
Market Data 
Markets 
AI
